-+ 0.00%
-+ 0.00%
-+ 0.00%

SCISPARC: SUBSIDIARY NEUROTHERA LABS PURSUES FDA ORPHAN DRUG DESIGNATION FOR ADULT TOURETTE SYNDROME DRUG; ENGAGES GOVERNMENT AND PUBLIC AFFAIRS FIRM RK STRATEGIES

Reuters·09/02/2026 12:17:00

Please log in to view news